Metabolic profiling of praziquantel enantiomers

Biochemical Pharmacology

Volumn 90, Issue 2, 2014, Pages 166-178

  Wang, Haina ^a,b   Fang, Zhong Ze ^b,c   Zheng, Yang ^d   Zhou, Kun ^c,e   Hu, Changyan ^d   Krausz, Kristopher W ^b   Sun, Dequn ^d   Idle, Jeffrey R ^b,f   Gonzalez, Frank J ^b  

^a SHANDONG UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^d SHANDONG UNIVERSITY   (China)

^e LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cytochromes P450; Enantioselective metabolism; In silico metabolomics; Praziquantel

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; PRAZIQUANTEL; RECOMBINANT ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHIRALITY; COMPUTER MODEL; CONFORMATION; CONTROLLED STUDY; DEHYDROGENATION; DRUG METABOLISM; DRUG STRUCTURE; ELECTROSPRAY; ENANTIOMER; FECES; GLUCURONIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METABOLITE; METABOLOMICS; MOLECULAR DOCKING; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINE;

CYTOCHROMES P450; ENANTIOSELECTIVE METABOLISM; IN SILICO METABOLOMICS; PRAZIQUANTEL;

ADMINISTRATION, ORAL; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FECES; ISOENZYMES; KINETICS; MALE; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; METABOLOME; MICE; MOLECULAR DOCKING SIMULATION; PRAZIQUANTEL; PROTEIN CONFORMATION; SCHISTOSOMICIDES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 84902276537     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.05.001     Document Type: Article

References (40)

1. D.S. Jenkins-Holick, and T.L. Kaul Schistosomiasis Urol Nurs 33 2013 163 170
2. P. Hagan, C.C. Appleton, G.C. Coles, J.R. Kusel, and L.A. Tchuem-Tchuente Schistosomiasis control: keep taking the tablets Trends Parasitol 20 2004 92 97 (Pubitemid 38121265)
3. S.D. Melman, M.L. Steinauer, C. Cunningham, L.S. Kubatko, I.N. Mwangi, and N.B. Wynn et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni PLoS Negl Trop Dis 3 2009 e504
4. J. Huang, S.P. Bathena, and Y. Alnouti Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer Drug Metab Pharmacokinet 25 2010 487 499
5. H. Meier, and G. Blaschke Investigation of praziquantel metabolism in isolated rat hepatocytes J Pharm Biomed Anal 26 2001 409 415 (Pubitemid 32727659)
6. C.M. Masimirembwa, and J.A. Hasler Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors Biochem Pharmacol 48 1994 1779 1783 (Pubitemid 24339004)
7. X.Q. Li, A. Bjorkman, T.B. Andersson, L.L. Gustafsson, and C.M. Masimirembwa Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data Eur J Clin Pharmacol 59 2003 429 442 (Pubitemid 37214951)
8. W. Ridtitid, M. Wongnawa, W. Mahatthanatrakul, J. Punyo, and M. Sunbhanich Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers Clin Pharmacol Ther 72 2002 505 513 (Pubitemid 36237721)
9. W. Ridtitid, K. Ratsamemonthon, W. Mahatthanatrakul, and M. Wongnawa Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers J Clin Pharm Therapeut 32 2007 585 593 (Pubitemid 350135111)
10. M.H. Wu, C.C. Wei, Z.Y. Xu, H.C. Yuan, W.N. Lian, and Q.J. Yang et al. Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica Am J Trop Med Hyg 45 1991 345 349
11. S.H. Xiao, and B.A. Catto Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni J Infect Dis 159 1989 589 592 (Pubitemid 19065913)
12. U. Staudt, G. Schmahl, G. Blaschke, and H. Mehlhorn Light and scanning electron microscopy studies on the effects of the enantiomers of praziquantel and its main metabolite on Schistosoma mansoni in vitro Parasitol Res 78 1992 392 397
13. R.M. Lima, M.A. Ferreira, T.M. Ponte, M.P. Marques, O.M. Takayanagui, and H.H. Garcia et al. Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS/MS: application to pharmacokinetics J Chromatogr B Analyt Technol Biomed Life Sci 877 2009 3083 3088
14. F. Li, A.D. Patterson, C.C. Hofer, K.W. Krausz, F.J. Gonzalez, and J.R. Idle A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics Biochem Pharmacol 81 2011 1043 1053
15. S. Giri, J.R. Idle, C. Chen, T.M. Zabriskie, K.W. Krausz, and F.J. Gonzalez A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse Chem Res Toxicol 19 2006 818 827 (Pubitemid 43939061)
16. C.H. Johnson, A.D. Patterson, J.R. Idle, and F.J. Gonzalez Xenobiotic metabolomics: major impact on the metabolome Annu Rev Pharmacol Toxicol 52 2012 37 56
17. Z.Z. Fang, K.W. Krausz, F. Li, J. Cheng, N. Tanaka, and F.J. Gonzalez Metabolic map and bioactivation of the anti-tumour drug noscapine Br J Pharmacol 167 2012 1271 1286
18. F. Li, J. Lu, and X. Ma Profiling the reactive metabolites of xenobiotics using metabolomic technologies Chem Res Toxicol 24 2011 744 751
19. Z.Z. Fang, Y.Y. Zhang, G.B. Ge, H. Huo, S.C. Liang, and L. Yang Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction Br J Clin Pharmacol 69 2010 193 199
20. D.R. Brocks, and F. Jamali Stereochemical aspects of pharmacotherapy Pharmacotherapy 15 1995 551 564
21. D.R. Brocks Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics Biopharm Drug Dispos 27 2006 387 406 (Pubitemid 44842300)
22. J.J. Torrado, M. Blanco, M. Farre, P. Roset, and A. Garcia-Arieta Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies Eur J Clin Pharmacol 66 2010 599 604
23. M. Perez-Trujillo, J.C. Lindon, T. Parella, H.C. Keun, J.K. Nicholson, and T.J. Athersuch Chiral metabonomics: 1H NMR-based enantiospecific differentiation of metabolites in human urine via direct cosolvation with beta-cyclodextrin Anal Chem 84 2012 2868 2874
24. K.M. Rentsch The importance of stereoselective determination of drugs in the clinical laboratory J Biochem Biophys Methods 54 2002 1 9 (Pubitemid 36126132)
25. H. Lu Stereoselectivity in drug metabolism Expert Opin Drug Metab Toxicol 3 2007 149 158 (Pubitemid 47316037)
26. F. Jamali, R. Mehvar, and F.M. Pasutto Enantioselective aspects of drug action and disposition: therapeutic pitfalls J Pharm Sci 78 1989 695 715 (Pubitemid 20101915)
27. W.H. Brooks, W.C. Guida, and K.G. Daniel The significance of chirality in drug design and development Curr Top Med Chem 11 2011 760 770
28. Y. Dong, J. Chollet, M. Vargas, N.R. Mansour, Q. Bickle, and Y. Alnouti et al. Praziquantel analogs with activity against juvenile Schistosoma mansoni Bioorg Med Chem Lett 20 2010 2481 2484
29. P. Andrews Praziquantel: mechanisms of anti schistosomal activity Pharmacol Ther 29 1985 129 156 (Pubitemid 16160382)
30. Y.H. Liu Levo-praziquantel versus praziquantel in experimental and clinical treatment of Schistosomiases japonica Chin Med J 106 2005 593 596
31. Y.H. Liu, M.X. Qian, X.G. Wang, J. Jia, Q.N. Wang, and Y.F. Jiang et al. Comparative efficacy of praziquantel and its optic isomers in experimental therapy of Schistosomiasis japonica in rabbits Chin Med J (Engl) 99 1986 935 940
32. T. Meyer, H. Sekljic, S. Fuchs, H. Bothe, D. Schollmeyer, and C. Miculka Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment PLoS Negl Trop Dis 3 2009 e357
33. N. Mano, T. Goto, A. Nikaido, T. Narui, and J. Goto Inhibition of the rat hepatic microsomal flurbiprofen acyl glucuronidation by bile acids J Pharm Sci 92 2003 2098 2108 (Pubitemid 37175640)
34. T. Nagao, T. Tanino, and M. Iwaki Stereoselective pharmacokinetics of flurbiprofen and formation of covalent adducts with plasma protein in adjuvant-induced arthritic rats Chirality 15 2003 423 428 (Pubitemid 36523130)
35. J.Q. Dong, and P.C. Smith Glucuronidation and covalent protein binding of benoxaprofen and flunoxaprofen in sandwich-cultured rat and human hepatocytes Drug Metab Dispos 37 2009 2314 2322
36. M.J. Bailey, and R.G. Dickinson Acyl glucuronide reactivity in perspective: biological consequences Chem Biol Interact 145 2003 117 137 (Pubitemid 36398426)
37. S.L. Dahl, and J.R. Ward Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent benoxaprofen Pharmacotherapy 2 1982 354 366 (Pubitemid 13140996)
38. R. Sawamura, N. Okudaira, K. Watanabe, T. Murai, Y. Kobayashi, and M. Tachibana et al. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide Drug Metab Dispos 38 2010 1857 1864
39. M.B. Sanchez, J.L. Herranz, C. Leno, R. Arteaga, A. Oterino, and E.M. Valdizan et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy Seizure: J Brit Epilepsy Assoc 19 2010 93 101
40. J. Cummings, B.T. Ethell, L. Jardine, G. Boyd, J.S. Macpherson, and B. Burchell et al. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives Cancer Res 63 2003 8443 8450 (Pubitemid 37553155)